Prime Medicine Inc (PRME)

Currency in USD
3.790
+0.090(+2.43%)
Closed·
3.820+0.030(+0.79%)
·
PRME is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.6553.840
52 wk Range
1.1106.940
Key Statistics
Prev. Close
3.7
Open
3.76
Day's Range
3.655-3.84
52 wk Range
1.11-6.94
Volume
2.14M
Average Vol. (3m)
2.68M
1-Year Change
187.1212%
Book Value / Share
0.68
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PRME Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.917
Upside
+82.50%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Prime Medicine Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Compare PRME to Peers and Sector

Metrics to compare
PRME
Peers
Sector
Relationship
P/E Ratio
−3.3x−2.5x−0.5x
PEG Ratio
−0.180.110.00
Price / Book
5.4x2.5x2.6x
Price / LTM Sales
141.4x118.0x3.2x
Upside (Analyst Target)
62.2%358.6%47.6%
Fair Value Upside
Unlock3.3%6.1%Unlock

Analyst Ratings

9 Buy
4 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.917
(+82.50% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Jones Trading
Buy5.00+31.93%-New CoverageApr 06, 2026
Oppenheimer
Buy11.00+190.24%-New CoverageMar 12, 2026
Citizens
Buy6.00+58.31%-MaintainMar 04, 2026
LifeSci Capital
Buy6.00+58.31%-New CoverageDec 23, 2025
Citi
Hold4.25+12.14%5.00MaintainNov 11, 2025

Earnings

Latest Release
Mar 03, 2026
EPS / Forecast
-0.22 / -0.43
Revenue / Forecast
842K / --
EPS Revisions
Last 90 days

PRME Income Statement

People Also Watch

34.410
PL
+1.41%
30.67
BEAM
+1.22%
475.76
CIEN
+1.83%
23.90
LUNR
+0.97%

FAQ

What Is the Prime Medicine (PRME) Stock Price Today?

The Prime Medicine stock price today is 3.790 USD.

What Stock Exchange Does Prime Medicine Trade On?

Prime Medicine is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Prime Medicine?

The stock symbol for Prime Medicine is "PRME."

What Is the Prime Medicine Market Cap?

As of today, Prime Medicine market cap is 655.190M USD.

What Is Prime Medicine's Earnings Per Share (TTM)?

The Prime Medicine EPS (TTM) is -1.352.

When Is the Next Prime Medicine Earnings Date?

Prime Medicine will release its next earnings report on May 07, 2026.

From a Technical Analysis Perspective, Is PRME a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Prime Medicine Stock Split?

Prime Medicine has split 0 times.

How Many Employees Does Prime Medicine Have?

Prime Medicine has 146 employees.

What is the current trading status of Prime Medicine (PRME)?

As of Apr 15, 2026, Prime Medicine (PRME) is trading at a price of 3.790 USD, with a previous close of 3.700 USD. The stock has fluctuated within a day range of 3.655 USD to 3.840 USD, while its 52-week range spans from 1.110 USD to 6.940 USD.

What Is Prime Medicine (PRME) Price Target According to Analysts?

The average 12-month price target for Prime Medicine is 6.917 USD, with a high estimate of 11 USD and a low estimate of 4.25 USD. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +82.50% Upside potential.

What Is the PRME Premarket Price?

PRME's last pre-market stock price is 3.730 USD. The pre-market share volume is 17,000.000, and the stock has decreased by 0.030, or 0.810%.

What Is the PRME After Hours Price?

PRME's last after hours stock price is 3.820 USD, the stock has decreased by 0.030, or 0.790%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.